Drugs / Onapristone
Trials 9
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-08-02 | Menarini Group | Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination menarini.com ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Onapristone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06938711 ↗ |
| Known as | Apristor | “Onapristone ER (Apristor)” NCT03909152 ↗ |
| Known as | ONA | “ONAWA is a window of opportunity, prospective, multicenter, phase 0 trial which evaluates the effect of onapristone (ONA) on proliferation after 3 weeks of treatment in...” NCT04142892 ↗ |
| Known as | ONA-XR | “The ONAWA trial (ClinicalTrials.gov ID: NCT04142892- Registered on January 6, 2021) was a single-arm study evaluating the preoperative effects of onapristone with...” PMID 42215464 ↗ May 2026 |
| Known as | Onapristona | ChEMBL registry synonym — accepted as the source's own label CHEMBL1908373 ↗ |
| Known as | ZK-299 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1908373 ↗ |
| Known as | ZK-98299 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1908373 ↗ |
| Action | Inhibit | “Onapristone is a type I progesterone receptor (PR) antagonist, which prevents PR- mediated DNA transcription.” PMID 30304013 ↗ Oct 2018 |
| Modality | Other / unclassified | “a type I antiprogestin” PMID 30304013 ↗ Oct 2018 |
| Route | Oral | “50 mg PO BID” NCT03909152 ↗ |
| Target | PGR | “Immunohistochemistry showed suppression of phospho-Ser294-PgR and p-STAT3, indicating effects on proliferation and endocrine pathways.” PMID 42215464 ↗ May 2026 |